



Sunday, December 11, 2022

Oral Presentations at ASH Annual Meeting

Note: All times listed are Central Time

Presentation	Speaker	Time/Location
409: Regulated Expression of GATA1 as a Gene Therapy Cure for Diamond-Blackfan Anemia	Richard A Voit, MD, PhD, Dana-Farber/Boston Children's	9:30 am 260-262
Education Program: Maximizing Outcomes in CLL	Jennifer Brown, MD, PhD, Chair and Speaker	9:30 - 10:45 am 265-268
Scientific Symposia: Building Dietary Evidence for Hematologic Malignancies - Mechanistic Insights	Catherine Marinac, PhD	9:30 - 10:45 am 217-219
Scientific Symposia: Introduction to Endogenous Retroelements and the Viral Mimicry Response in Cancer Therapy	Gabriel K. Griffin, MD	9:30 - 10:45 am 288-290
Scientific Program: Cell Competition and Clonal Hematopoiesis	Ann Mullally, Brigham and Women's	9:30 - 11:05 am New Orleans Theater AB
452: Mutant Srsf2 Diminishes Jak2V617F-Induced Erythrocytosis in Mice and Is Associated with Lower Hemoglobin in Patients with Chronic Phase JAK2-Mutant MPN	Anna E Marneth, PhD	9:45 am 275-277
410: Manipulation of Thymidine Nucleotide Metabolism Controls Human Telomere Length and Promotes Telomere Elongation in Dyskeratosis Congenita Patient Derived Cells	William Mannherz, BS, Dana-Farber/Boston Children's	9:45 am 260-262
482: CAR-T Cell Infusion Results in Activation of CD160+/NKG2D+/CCL5+ Non-CAR CD8+ Cytotoxic 'Bystander' T Cells in Both Non-Human Primates (NHP) and Patients Receiving B-Cell-Directed CAR-Ts	Ulrike Gerdemann, MD, Dana-Farber/Boston Children's	9:45 am 388-390
440: A Pilot Study of Axicabtagene Ciloleucef for the Treatment of Relapsed/Refractory Primary and Secondary Central Nervous System Lymphoma (CNSL)	Caron A. Jacobson, MD, MMSc	9:45 am La Nouvelle Orleans Ballroom AB
501: Implementation of Electronic Alerts to Improve Clinician Management of Heparin Induced Thrombocytopenia	Becky Zon, MD	10:00 am 291-292
490: A Phase 2 Study of Pembrolizumab (MK-3475) after Autologous Stem Cell	Mwanasha H. Merrill, MD	10:15 am 220-222



Sunday, December 11, 2022

Transplantation in Patients with T-Cell Non-Hodgkin Lymphoma		
Special-Interest Session: How to Peer Review a Scientific Paper	Panelist: Leslie S. Kean, MD, PhD, Dana-Farber/Boston Children's	11:15 am - 12:15 pm 252-254
571: A Real-World Evidence Comparison of 1-Year Overall Survival and Relapse-Free Survival Between Patients Treated with Abatacept in Combination with a Calcineurin Inhibitor and Methotrexate Versus Antithymocyte Globulin or Post-Transplant Cyclophosphamide Following Allogeneic Hematopoietic Cell Transplantation	Leslie S. Kean, MD, PhD, Dana-Farber/Boston Children's	12:00 pm 208-210
568: Mezigdomide (CC-92480), a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD), Combined with Dexamethasone (DEX) in Patients with Relapsed/Refractory Multiple Myeloma: Preliminary Results from the Dose-Expansion Phase of the CC-92480-MM-001 Trial	Paul G. Richardson, MD	12:45 pm New Orleans Theater C
649: Targeted Deletion of Activated T Cells with a Single Dose of Anti-CD137-Antibody Drug Conjugate Protects Against Acute GVHD (aGVHD) and Promotes Tolerogenic T Cell Reconstitution after Haplo-Identical Hematopoietic Stem Cell Transplantation (HSCT)	Ulrike Gerdemann, MD	4:30 pm 208-210
642: Bioprocessing of MIR17HG Results in Long and Short Noncoding RNAs with Targetable Tumor-Promoting Activity in Multiple Myeloma	Eugenio Morelli, MD	4:30 pm New Orleans Theater AB
Education Spotlight Session: Bone Marrow Failure Syndromes – Diagnostic Principles in 2022	Mark Fleming, MD, DPhil, Dana-Farber/Boston Children's	4:30-5:45 pm
626: Preliminary Safety and Efficacy from Apex, a Phase 2 Study of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Adults with Advanced Systemic Mastocytosis (AdvSM)	Daniel J. DeAngelo, MD, PhD	4:45 pm 217-219
639: Intergenic Non-Switch Immunoglobulin Translocations Are Frequently Observed in Genomically Unstable Multiple Myeloma	Mehmet K. Samur, PhD	5:00 pm New Orleans Theater AB
633: Evolutionary History of Transformation from Chronic Lymphocytic Leukemia to Richter Syndrome	Erin Parry, MD, PhD	5:00 pm R02-R05



Sunday, December 11, 2022

641: The ERK1/2 Regulator WNK2 Shows Novel Alternative Splicing Aberrations That Support Tumor Growth in MYD88 Mutated Waldenström's Macroglobulinemia

Maria Luisa Guerrero, MD

5:30 pm
New Orleans Theater AB

636: Immuno-Genetic Changes Underlie Response to Immune Checkpoint Blockade Therapy in Richter's Syndrome Mouse Models

Elisa Ten Hacken, PhD

5:45 pm
R02-R05
